Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

How Ozempic helps manage fatty liver disease Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist that manages blood sugar by increasing insulin levels, slowing gastric emptying ...

GLP-1 agonist medications such as Ozempic and Wegovy are in high demand ... 53 percent lower risk of liver cancer, 48 percent lower risk of ovarian cancer, 46 percent lower risk of colorectal ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Experts say semaglutide may be a much-needed treatment option for a liver disease with few current therapies. Ozempic is effective in treating a severe form of liver disease that affects nearly 2 ...

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Discover how Ozempic is transforming America's eating, shopping, and dressing habits, with insights from Dr. Alexandra Sowa's book.

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target obesity drug to reach the market.